2019
DOI: 10.12688/f1000research.17964.1
|View full text |Cite
|
Sign up to set email alerts
|

Does the mouse tail vein injection method provide a good model of lung cancer?

Abstract: Lung cancer drug development requires screening in animal models. We aimed to develop orthotopic models of human non-small lung cancer using A549 and H3122 cells delivered by tail vein injection. This procedure has been used previously for a mouse lung cancer (Lewis lung carcinoma) and as a model of human breast cancer metastasis to lung. We report that the procedure led to poor animal condition 7-8 weeks after injection, and produced lesions in the lungs visible at necropsy but we were unable identify individ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
2
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 11 publications
1
2
0
1
Order By: Relevance
“…To obtain the primary tumor model, we administered the cancer cells into the mammary pad (the orthotopic model), and for metastasis formation, we administered cancer cells via the tail vein. After the injection of cancer cells into the tail vein, metastases are formed in the lungs [47][48][49], which we confirmed histopathologically in our model. The biodistribution study of the DDS indicated that the location of the tumor lesion influenced the accumulation of the spheres.…”
Section: Discussionsupporting
confidence: 80%
“…To obtain the primary tumor model, we administered the cancer cells into the mammary pad (the orthotopic model), and for metastasis formation, we administered cancer cells via the tail vein. After the injection of cancer cells into the tail vein, metastases are formed in the lungs [47][48][49], which we confirmed histopathologically in our model. The biodistribution study of the DDS indicated that the location of the tumor lesion influenced the accumulation of the spheres.…”
Section: Discussionsupporting
confidence: 80%
“…Following the dosing regimens of EGFR-TKIs, at day 0, 2 × 10 6 PC9-luciferase cells were injected into the tail vein of mice. Although six mice were taken per group, one mouse from control and two from each treatment group died during the tail vein injections, most likely due to thromboembolism, as reported earlier [6] . Thus, five mice in the control group and four mice in each treatment group were used for further experiments.…”
mentioning
confidence: 74%
“…It has high tumorigenicity and compatibility with the innate murine immune system. Both immune and tumor responses can be quantified [ 26 ].…”
Section: Methodsmentioning
confidence: 99%